202 related articles for article (PubMed ID: 1973362)
21. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
Kury FD; Schneeberger C; Sliutz G; Kubista E; Salzer H; Medl M; Leodolter S; Swoboda H; Zeillinger R; Spona J
Oncogene; 1990 Sep; 5(9):1403-8. PubMed ID: 1699198
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.
Schneider PM; Hung MC; Chiocca SM; Manning J; Zhao XY; Fang K; Roth JA
Cancer Res; 1989 Sep; 49(18):4968-71. PubMed ID: 2569928
[TBL] [Abstract][Full Text] [Related]
23. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
24. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
25. Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression.
Shiga K; Shiga C; Sasano H; Miyazaki S; Yamamoto T; Yamamoto M; Hayashi N; Nishihira T; Mori S
Anticancer Res; 1993; 13(5A):1293-301. PubMed ID: 7902061
[TBL] [Abstract][Full Text] [Related]
26. Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents.
Futscher BW; Erickson LC
Cancer Res; 1990 Jan; 50(1):62-6. PubMed ID: 2104539
[TBL] [Abstract][Full Text] [Related]
27. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.
Lichtenstein A; Berenson J; Gera JF; Waldburger K; Martinez-Maza O; Berek JS
Cancer Res; 1990 Nov; 50(22):7364-70. PubMed ID: 1977519
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers.
Freeman MR; Washecka R; Chung LW
Cancer Res; 1989 Nov; 49(22):6221-5. PubMed ID: 2572319
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.
Liu C; Tsao MS
Am J Pathol; 1993 Apr; 142(4):1155-62. PubMed ID: 8097369
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
31. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.
Hollstein MC; Smits AM; Galiana C; Yamasaki H; Bos JL; Mandard A; Partensky C; Montesano R
Cancer Res; 1988 Sep; 48(18):5119-23. PubMed ID: 3044581
[TBL] [Abstract][Full Text] [Related]
32. HER-2/neu oncogene expression and proliferation in breast cancers.
Bacus SS; Ruby SG; Weinberg DS; Chin D; Ortiz R; Bacus JW
Am J Pathol; 1990 Jul; 137(1):103-11. PubMed ID: 1973597
[TBL] [Abstract][Full Text] [Related]
33. Human lung cancers growing on extracellular matrix: expression of oncogenes and growth factors.
Pavelic K; Antonic M; Pavelic L; Pavelic J; Pavelic Z; Spaventi S
Anticancer Res; 1992; 12(6B):2191-6. PubMed ID: 1363516
[TBL] [Abstract][Full Text] [Related]
34. Similar early gene responses to ligand-activated EGFR and neu tyrosine kinases in NIH3T3 cells.
Koskinen P; Lehväslaiho H; MacDonald-Bravo H; Alitalo K; Bravo R
Oncogene; 1990 Apr; 5(4):615-8. PubMed ID: 1970155
[TBL] [Abstract][Full Text] [Related]
35. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
36. C-myc, N-myc, N-ras, and c-erb-B: lack of amplification or rearrangement in human medullary thyroid carcinoma and a derivative cell line.
Yang KP; Castillo SG; Nguyen CV; Hickey RC; Samaan NA
Anticancer Res; 1990; 10(1):189-92. PubMed ID: 2185686
[TBL] [Abstract][Full Text] [Related]
37. Oncogene and HSP-70 expression in primary tumor cell cultures of renal cell carcinoma compared to their corresponding cell line.
Köhler G; Veelken H; Rosenthal F; Mackensen A; Lindemann A; Schaefer HE; Lahn M
Anticancer Res; 1997; 17(5A):3225-31. PubMed ID: 9413152
[TBL] [Abstract][Full Text] [Related]
38. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
[TBL] [Abstract][Full Text] [Related]
39. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
40. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
